Turinabol is prescribed in patients that suffer from protein synthesis disorders, diverse genesis of cachexia, trauma, extensive burns after irradiation infectious diseases, muscular dystrophy, osteoporosis, negative nitrogen balance corticosteroid therapy, aplastic anemia and hypo.
Turinabol has an anabolic effect, and is used as a secondary medicine in the therapy of protein catabolism with negative nitrogen balance (deficiency, excessive consumption or loss of protein) in the elderly with denutrition status and cachexia, in asthenia, different origin cachexia, in vast combustion and bedsores, after surgery, infections and major trauma, osteoporosis, continuous use of glucocorticoids , and aplastic anemia; hemolytic anemia, chronic anemia, chronic renal failure, anemia caused by tumors, lymphomas and leukemia, idiopathic thrombocytopenia, muscle atrophy in patients with AIDS in pediatric practice in case of increasing retention, anorexia (lack of appetite), weight reduction, etc.
Turinabol is contraindicated if the patient suffers from hypersensitivity to the drug,male breast cancer, breast carcinoma in women with hypercalcemia, ovarian cancer, CPI, severe atherosclerosis, nephritis, nephrotic syndrome, adenoma of prostate cancer, renal and hepatic dysfunction, acute and chronic prostatitis, pregnancy, lactation period until sexual maturation.
Turinabol treatment does not substitute the basic therapy it is used as a secondary helpful therapy. Turinabol therapy period depends on the patient's responsiveness and the evolution of possible side effects.
Turinabol administered dose for adults is 20-50 mg daily. Turinabol therapy length is considered 2-6 weeks.
As an androgenic and anabolic steroid, Turinabol interacts with the cell membranes and interact with cytoplasmic receptors and the formed band is transported into the nucleus where it acts on specific nuclear receptors. This active complex interacts with DNA and acts as a transcription factor that induce the synthesis process of RNA and specific proteins.
This medicine has a visible anabolic effect that is evident in lean muscles ad bones changes, and other tissues with high division (bone marrow, mucous etc.). Turinabol contributes to a more developed muscle mass and growth (less effect as testosterone, but can be increased using other anabolics). The administration of this drug has a strong effect on calcium fixation in bones, possibly due to a high level of matrix protein formation and/or reduction in parathyroid hormone responsiveness of bone tissue. The main purpose consists in obtaining anabolic metabolic changes: a normal nitrogen balance (nitrogen retention), high protein synthesis, decrease catabolism of amino acids, phosphorus and potassium retention. Turinabol stimulates hematopoiesis, especially erythropoiesis (erythropoietin formation increases) and favors leucopoiesis and platelet formation.
In case, a treatment with anabolic steroids is indicated the patients should be attention about possible side effects, and they seek a doctor immediately at their appearance. If symptoms of virilization take place in patients (deepening of the voice, hirsutism, acne, clitoromegaly) then Turinabol therapy need to be discontinued in order to avoid irreversible changes.
Medicines of this group are predisposed to induce suppression of plasma coagulation factors II, V, VII, X this requires strict monitoring, including administration of indirect anticoagulants.
Turinabol therapy requires monitoring liver function parameters (transaminases, alkaline phosphatase, and bilirubin) and lipid (cholesterol and low-density lipoproteins). In old patients can be seen a high level of hypertrophy and prostate carcinoma that needs close inspection.
Turinabol therapy in children requires strict monitoring because they may accelerate epiphyseal closure, effect that may last for 6 months after the cycle is discontinued. From this point of view is important to consult with a health specialist about rationality administration of this medicine, following radiological bone maturation.
In case the therapy needs high doses of anabolic steroids then it is indicated a periodic monitoring of hemoglobin and hematocrit level due to possible polycythemia.
Turinabol can cause liver, endocrine, neurological, metabolism and mixed disorders.
Liver unwanted effects: cholestatic jaundice, rare hepatocytes with hepatic necrosis, hepatocellular neoplasms. It can cause changes in levels of biochemical parameters: increase the level of bilirubin, alkaline phosphatase, transaminases. Cholestatic jaundice may appear after 6 weeks or more of therapy (home is considered as toxic) and is manifested by hyperbilirubinemia bile stasis in the capillaries and increase alkaline phosphatase content. A long period use of Turinabol may increase the frequency of liver tumors.
Endocrine disorders: Turinabol rarer than other anabolic steroids in men can induce: reduced spermatogenesis and sexual potency (secondary to decrease gonadotropins and testosterone secretion with testicular atrophy and oligospermia) prostate hypertrophy (mainly in elderly patients), epididymitis, chronic priapism. In boys may cause early sexual maturation, frequent erections, increasing the risk of growing retention.
Neurological disorders: excitation, insomnia, depression, confusion.
Metabolism: reduced glucose tolerance, increase low-density lipoproteins levels (LDL ), accelerated phase creatinine, increased level of creatine, swelling due to sodium and water reabsorption, retention of potassium, calcium, phosphorus. In people long attached to the bed can be found hypercalcemia
Miscellaneous: during puberty may close early epiphyseal areas with increased retention.
Overdose situations or not met.